Theralase Technologies Inc. V.TLT

RE:The Erosion Of Science/Research...

[Hempdoc]

Hempdoc wrote:

for the betterment of society, or for the enrichment of Big Pharma & all of those who have their hands in Pharm's deep pockets (academicians, so-called independent experts, the MSM)? So many instances where HCQ is being intentionally maligned in the research/clinical trial world...sad reality.  Also, just because a study may be randomized/placebo-controlled/double-blinded doesn't make it valid, or even on point.  You can tailor any study to your (Big Pharma's) desired outcome...like practically overdosing HCQ cohorts in already hospitalized/critically ill/high-risk patients (many with cardiac disease/failure).  It's not too difficult to tarnish a drug if there's enough $ incentive.

One simply needs to keep his eye on legitimate studies that not only "properly dose", but also "properly test/utilize" HCQ as a "combination" drug (not monotherapy) in an "ambulatory" setting. "Early use" is key for any anti-viral in general...once you wait until someone is critically ill, oxygen-requiring, mechanically ventilated or in the ARD stage, the viral load is much too high & "any" anti-viral will show little to no benefit in terms of reducing mortality.  Unfortunately, too few studies exist looking at HCQ properly.  

https://healthimpactnews.com/2020/editors-of-the-lancet-and-the-new-england-journal-of-medicine-pharmaceutical-companies-are-so-financially-powerful-they-pressure-us-to-accept-papers/

Forgot to mention the FDA/CDC-Big Pharma connection.  TLT's battle won't necessarily be the science nor the financing imo.   With IND approval in hand, I would expect to see a significant increase in US accruals/treated patients later this year.  If not, my guess is many patients will be steered towards Keytruda & the like.  Accrual is our key to the promised land.  Building relationships with community-based organizations/physicians would be a good start.  Let's hope our TMO is getting the job done...imo a total of 4 to 6 committed trial sites in the US may be a money-wise move & more than enough additional data for early approval if the science continues to prove itself.